TAK-677 (Dainippon/Takeda).
Curr Opin Investig Drugs
; 3(11): 1624-8, 2002 Nov.
Article
en En
| MEDLINE
| ID: mdl-12476963
ABSTRACT
TAK-677 is a beta3-adrenergic agonist under development by Dainippon and Takeda for the potential treatment of non-insulin dependent diabetes and obesity. In March 2001, Takeda initiated a phase II trial in the US for Type II diabetes [411811], [416686], [423455]. By December 2001, the compound was also in phase II trials for obesity in the US, and Dainippon was conducting phase II studies in Japan for diabetes [458750].
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tecnología Farmacéutica
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Indoles
/
Obesidad
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Investig Drugs
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2002
Tipo del documento:
Article